A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as colorectal cancer, in the five years.
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.